Five unit bolus oxytocin at cesarean delivery in women at risk of atony: a randomized, double-blind, controlled trial
- PMID: 20889945
- DOI: 10.1213/ANE.0b013e3181f8930a
Five unit bolus oxytocin at cesarean delivery in women at risk of atony: a randomized, double-blind, controlled trial
Abstract
Background: I.v. bolus oxytocin is used routinely during cesarean delivery to prevent postpartum hemorrhage. Its adverse hemodynamic effects are well known, resulting in a recent change in dose from 10 IU to 5. Whether a 5 IU bolus has any advantages over infusion alone is unclear. We tested the hypothesis that a 5 IU i.v. bolus of oxytocin before the initiation of a continuous infusion decreases the need for additional uterotonic drugs in the first 24 hours after delivery in women with risk factors for uterine atony undergoing cesarean delivery, compared with infusion alone.
Methods: A prospective, randomized, double-blind, controlled trial was conducted in 143 subjects undergoing cesarean delivery with at least 1 risk factor for uterine atony. Subjects received 5 IU bolus of oxytocin or normal saline i.v. over 30 seconds after umbilical cord clamping. All subjects received an infusion of 40 IU oxytocin in 500 mL normal saline over 30 minutes, followed by 20 IU in 1 L over 8 hours. The primary outcome was the need for additional uterotonics in the first 24 hours after delivery. Secondary outcomes included uterine tone as assessed by the surgeon (5-point Likert scale: 0 = "floppy," 4 = "rock hard"), estimated blood loss, side effects of bolus administration, and the oxytocin bolus-placental delivery interval.
Results: There was no difference in the need for additional uterotonic drugs in the first 24 hours between groups. There was a significant difference in uterine tone immediately after placental delivery (P < 0.01) (2.8 in the oxytocin group [95% confidence interval 2.6-3.0] vs 2.2 in the saline group [95% confidence interval 1.8-2.5]), which disappeared after 5 minutes. There were no differences in observed or reported side effects between groups.
Conclusions: We found that a 5 IU i.v. bolus of oxytocin added to an infusion did not alter the need for additional uterotonic drugs to prevent or treat postpartum hemorrhage in the first 24 hours in women undergoing cesarean delivery with risk factors for uterine atony, despite causing an initial stronger uterine contraction. Our study was not powered to find a difference in side effects between groups. These results suggest that an oxytocin infusion may be adequate without the need for a bolus, even in high-risk patients.
Similar articles
-
Utilization of carbetocin for prevention of postpartum hemorrhage after cesarean section: a randomized clinical trial.Arch Gynecol Obstet. 2009 Nov;280(5):707-12. doi: 10.1007/s00404-009-0973-8. Epub 2009 Feb 20. Arch Gynecol Obstet. 2009. PMID: 19229549 Clinical Trial.
-
Up-down determination of the ED(90) of oxytocin infusions for the prevention of postpartum uterine atony in parturients undergoing Cesarean delivery.Can J Anaesth. 2010 Jun;57(6):578-82. doi: 10.1007/s12630-010-9297-1. Epub 2010 Mar 18. Can J Anaesth. 2010. PMID: 20238255 Clinical Trial.
-
Intramuscular oxytocin versus intravenous oxytocin to prevent postpartum haemorrhage at vaginal delivery (LabOR trial): study protocol for a randomised controlled trial.Trials. 2017 Nov 15;18(1):541. doi: 10.1186/s13063-017-2269-9. Trials. 2017. PMID: 29141679 Free PMC article. Clinical Trial.
-
Oxytocin for labour and caesarean delivery: implications for the anaesthesiologist.Curr Opin Anaesthesiol. 2011 Jun;24(3):255-61. doi: 10.1097/ACO.0b013e328345331c. Curr Opin Anaesthesiol. 2011. PMID: 21415725 Review.
-
Prevention of postpartum haemorrhage with the oxytocin analogue carbetocin.Eur J Obstet Gynecol Reprod Biol. 2009 Nov;147(1):15-20. doi: 10.1016/j.ejogrb.2009.06.018. Epub 2009 Jul 17. Eur J Obstet Gynecol Reprod Biol. 2009. PMID: 19616358 Review.
Cited by
-
Uterotonic agents for preventing postpartum haemorrhage: a network meta-analysis.Cochrane Database Syst Rev. 2018 Apr 25;4(4):CD011689. doi: 10.1002/14651858.CD011689.pub2. Cochrane Database Syst Rev. 2018. Update in: Cochrane Database Syst Rev. 2018 Dec 19;12:CD011689. doi: 10.1002/14651858.CD011689.pub3. PMID: 29693726 Free PMC article. Updated.
-
Higher-dose oxytocin and hemorrhage after vaginal delivery: a randomized controlled trial.Obstet Gynecol. 2012 Feb;119(2 Pt 1):293-300. doi: 10.1097/AOG.0b013e318242da74. Obstet Gynecol. 2012. PMID: 22227638 Free PMC article. Clinical Trial.
-
Effect of a High-Rate Versus a Low-Rate Oxytocin Infusion for Maintaining Uterine Contractility During Elective Cesarean Delivery: A Prospective Randomized Clinical Trial.Anesth Analg. 2017 Mar;124(3):857-862. doi: 10.1213/ANE.0000000000001658. Anesth Analg. 2017. PMID: 28212181 Free PMC article. Clinical Trial.
-
Uterotonic agents for preventing postpartum haemorrhage: a network meta-analysis.Cochrane Database Syst Rev. 2018 Dec 19;12(12):CD011689. doi: 10.1002/14651858.CD011689.pub3. Cochrane Database Syst Rev. 2018. Update in: Cochrane Database Syst Rev. 2025 Apr 16;4:CD011689. doi: 10.1002/14651858.CD011689.pub4. PMID: 30569545 Free PMC article. Updated.
-
Oxytocin infusion for maintenance of uterine tone under prophylactic phenylephrine infusion for prevention of post-spinal hypotension in cesarean delivery: a prospective randomised double-blinded dose-finding study.BMC Pregnancy Childbirth. 2023 Dec 6;23(1):840. doi: 10.1186/s12884-023-06165-5. BMC Pregnancy Childbirth. 2023. PMID: 38057742 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical